

# MVT *in* Silico

*A life sciences innovation company.*

London Ontario, Canada.

Presenter: Dr. SR Kharche.

Sanjay R KHARCHE.

Ph.D.

CEO.

sumus@mvtinsilico.ca

5198780685.

London, Canada.

Every product *should* be verified to be  
safe & efficient  
before sending it to the consumer.


# Not many products are!

*Which includes some frequently used important medical treatments!!*

# ?

## Problem.

Life sciences  
(MedTech & BioTech)  
innovation faces many hurdles,  
limits tech translation.  
Present industry capacity is  
fragmented, insufficient.





# Solution.

MVT *in Silico*'s  
two part proprietary platform  
addresses the industry's pain  
points,  
is designed for  
innovation as a routine.

CRO solutions,  
internal innovation programs.

Validation stage!

Computer  
experiments:

**mvt**  
**Software**  
**Suite.**

*In vitro*  
experiments:

**mvt**  
**NAMs.**



1.  
Dev efficiency.

- 60% reduction in materials/animal use.
- Shorter timelines limit personnel costs.
- Other savings.



2.  
Shorter dev  
cycles.

50% shorter timelines  
from design to  
prototype, weeks to  
months.



3.  
Improved  
success rates.

Platform generated  
evidence feeds into  
patent applications.

Business model.

**Diverse  
relationships  
impart  
resilience,  
channel our  
innovation to  
assets, provide  
routes for our  
public service.**



Competitive advantages.

# MVTiS has many advantages.

We are a one stop shop for solutions to a wide spectrum of hard to solve problems in the life sciences.

● MedTech. ● BioTech.

	CFD Life (Japan).	Computational Life (Italy).	Intrepid labs, Toronto.	StokedBio, Hamilton.	MVT in Silico. Canada.
	●	●	●	●	● ●
Synthetic data.	✓	✓	✓	✓	✓
In vitro data.			✓		✓
Toxicity/ Failure opt.			✓	✓	✓
Device opt.	✓	✓			✓
Drug opt.			✓	✓	✓
Knowledge driven AI.	✓	✓	✓	✓	✓

● MedTech.  
● BioTech.

Revenue streams.

**Targeting  
high value,  
high impact  
markets.**

Our mission is to address hard to  
solve technological problems.

**Specializations & ongoing projects.**

**DDS.**



**Blood flow  
disorders.**



**Hormonal  
disorders.**



**Molecular  
& genetic  
defects.**



**Target markets.**

**Women's  
health.  
(> \$50B).**

**Hypertension.  
(> \$20B).**

**Rare  
diseases &  
orphan  
drugs.  
(societal  
impact).**



Team.

**An expert team  
poised for  
success,  
additional skill  
sets upcoming.**



**Dr. Sanjay Kharche.**  
Founder, CEO, CSO.



**Prof. D. G. Welsh.**  
Advisor. Pharmacology  
expert.

**CFO.**  
*Under  
negotiation.*

**IP expert.**  
*Under  
negotiation.*

**Marketing &  
sales.**  
*Under  
negotiation.*



**Harpreet Kaur.**  
Business strategy  
manager.




**Yihang Cheng.**  
R&D officer.

Progress.

# Milestones: Past & future.

Adopting a lean approach,  
there is steady progress with  
revenue expected in Q2 2026.




Ask and purpose.

# **An investment opportunity: We are raising \$1.5M, and leverage it to \$3M.**

*With a runway to Q4 2027 (scheduled next raise), your \$\$ ensure expansion, a large ROI, and puts us together on a growth & profit trajectory!*

Sunday, May 18, 2025

2.4% each for fractional CFO, marketing & sales, IP professional, business support.



Other: Accounting, payroll, travel, training, misc.

Tech salaries  
(31.3%).

Lab  
equipment  
(13.3%).

IP & legal  
(13.3%).

Lab set up  
(6.6%).

Corporate legal  
(6.6%).

Tech support  
(6.6%).

MVT in Silico.

**Extra slides.**

# How it works.

A combination of our life sciences validation stage software suite and lab rigs enable our operations of product development and CRO services.

